反応式
C([N:4]1[CH2:9][CH2:8][N:7]([C:10]2[N:11]=[CH:12][C:13]3[CH:19]=[C:18]([C:20]4[CH:25]=[CH:24][CH:23]=[CH:22][CH:21]=4)[C:17]([C:26]4[CH:33]=[CH:32][C:29]([CH:30]=O)=[CH:28][CH:27]=4)=[N:16][C:14]=3[N:15]=2)[CH2:6][CH2:5]1)(=O)C.F[C:35](F)(F)[C:36]([OH:38])=O.[NH:41]1[CH2:46][CH2:45][CH:44]([C:47]2[NH:48][C:49]([C:52]3[CH:57]=[CH:56][CH:55]=[CH:54][N:53]=3)=[N:50][N:51]=2)[CH2:43][CH2:42]1.CCN(CC)CC.CC(O)=O.C(O[BH-](OC(=O)C)OC(=O)C)(=O)C.[Na+]>CN(C=O)C.CCOC(C)=O>[C:36]([N:4]1[CH2:5][CH2:6][N:7]([C:10]2[N:11]=[CH:12][C:13]3[CH:19]=[C:18]([C:20]4[CH:21]=[CH:22][CH:23]=[CH:24][CH:25]=4)[C:17]([C:26]4[CH:33]=[CH:32][C:29]([CH2:30][N:41]5[CH2:46][CH2:45][CH:44]([C:47]6[NH:48][C:49]([C:52]7[CH:57]=[CH:56][CH:55]=[CH:54][N:53]=7)=[N:50][N:51]=6)[CH2:43][CH2:42]5)=[CH:28][CH:27]=4)=[N:16][C:14]=3[N:15]=2)[CH2:8][CH2:9]1)(=[O:38])[CH3:35]参加物
8
反応物 5
生成物 1
試薬・触媒・溶媒 2
実験手順
To a solution of 4-[2-(4-acetylpiperazin-1-yl)-6-phenylpyrido[2,3-d]pyrimidin-7-yl]benzaldehyde (3-2; 61 mg, 0.14 mmol) in DMF (5 mL) was added 2-(5-piperidin-4-yl-4H-1,2,4-triazol-3-yl)pyridine trifluoroacetate (58 mg, 0.17 mmol) followed by Et3N (80 μL, 0.51 mmol), AcOH (91 μL, 1.5 mmol) and sodium triacetoxyborohydride (59 mg, 0.28 mmol). The reaction mixture was allowed to stir for 12 hr then diluted with EtOAc and washed with NaHCO3 (sat.), dried with MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (100% CH2Cl2 to 85% CH2Cl2/15% MeOH) to afford the title compound. LRMS m/z (M+H) Calcd.: 651.7, found 651.3.
後処理
- washwashed with NaHCO3 (sat.)
- dry with materialdried with MgSO4
- filtrationfiltered
- concentrationconcentrated under reduced pressure
- customThe residue was purified by silica gel chromatography (100% CH2Cl2 to 85% CH2Cl2/15% MeOH)
出典と根拠
- ORDレコード
- ord-8682c367792c4693b4d39c1d3acfd771
- 出典データセット
- uspto-grants-2009_06
- 特許番号
- US07544677B2
関連ノート
読み込み中…